Section 1:
Diagnosis and Burden of UC in KSA Practice
1.01
Which of the following specialists are involved in the identification, diagnosis, management, and care of patients with ulcerative colitis (UC) throughout their treatment journey?
1.02
What can be the added value of adopting a multi-disciplinary approach in the management of UC?
1.03
From which regions of KSA do you receive the referred patients?
1.04
In your institution, what is the percentage of UC caseload from the total inflammatory bowel disease (IBD) cases?
1.05
What are the causes of the increased incidence of UC or Crohn's disease in KSA?
1.06
What is the percentage of employed patients from the total UC cases you have encountered?
1.07
What is the percentage of moderate-to-severe active UC cases from the total pool of encountered cases?
1.08
What is the most common age group that you encounter among moderate-to-severe UC patients?
1.09
What are the most common symptoms reported by UC patients?
1.10
Which of these patient factors can be predictive of moderate-to-severe UC? [Select all that apply]
1.11
What are the most common manifested symptoms of moderate-to-severe active UC cases?
1.12
Which of the following is the most reliable scoring system regarding the identification of moderate-to-severe UC?
Section II:
UC Management Landscape in KSA
2.01
Which of the following UC management guidelines do you adopt in your clinical practice?
2.02
What are your treatment goals/objectives in the management of moderate-to-severe UC? [Select all that apply]
2.03
How do you routinely assess the treatment response in UC patients? [Select all that apply]
2.04
How often do you perform endoscopic reassessment for moderate-to-severe UC patients? [Select all that apply]
2.05
How do usually assess clinical remission in UC patients?
2.06
What are the factors affecting your choice of medications in case of refractory/treatment-resistant patients?
2.07
Who are the parties involved in the decision of switching between medications? [Select all that apply]
2.08
What is the most common patient fears regarding their choice of treatment modality?
2.09
According to your clinical practice, which of the following medications would you initiate for UC patients after failure of anti-TNF agents?
2.10
According to your clinical practice, which of the following medications would you consider for UC patients who developed corticosteroid dependence?
2.11
How do you identify treatment failure with anti-TNF agents? [Select all that apply]
2.12
Biosimilar treatment options are an important and vital part of our treatment plans. From 1–10, rate your knowledge of biosimilars. [while 1 marks the lowest knowledge and 10 marks the highest knowledge]
2.13
What are the most common issues you face when it comes to the use of biosimilars?
2.14
What are the available resources to understand the comparability, interchangeability, efficacy, and safety of biosimilars?
2.15
What are the most common biosimilars available for use in your clinical practice?
2.16
Would you prescribe a biosimilar in indications that have been granted FDA approval based on extrapolation?
2.17
Which of the following aligns well with your perspective regarding the switch from one biosimilar to another one?
2.18
How comfortable do you feel prescribing biosimilars to your patients?
2.19
What is your main concern about prescribing biosimilars?
2.20
When considering biosimilars as a treatment option, the importance of cost saving for my patients is:
2.21
Would you consider switching a stabilized patient on a specific agent to its biosimilar?
2.22
Would you consider monitoring for adverse events in patients receiving biosimilars?
2.23
Given the results of the OCTAVE studies regarding the equal efficacy of tofacitinib regardless of prior exposure to an anti-TNF agent, have you prescribed tofacitinib to anti-TNF-naive patients?
2.24
Which of the following factors affect the bioavailability of monoclonal antibodies, including anti-TNF agents? [Select all that apply]
2.25
Unlike monoclonal antibodies, the bioavailability of tofacitinib is not affected by low albumin levels. Would you administer tofacitinib instead of anti-TNF agents in patients with low albumin levels after the failure of conventional medications?
2.26
Which of the following medications would you prescribe for UC patients who are secondary non-responders to an anti-TNF agent?
2.27
According to your clinical practice, what is the percentage of patients who achieved a year-long clinical remission when tofacitinib is administered?
2.28
Which factors indicate an early de-escalation of tofacitinib dose to 5 mg? [Select all that apply]
2.29
What is the percentage of patients who maintained their clinical remission on tofacitinib 5 mg?
2.30
What is the longest period of clinical remission using tofacitinib 5 mg that you have encountered?
2.31
How do you manage patients who lose response after tofacitinib dose de-escalation?
2.32
Which factors would encourage you to prescribe tofacitinib over other JAKis? [Select all that apply]
2.33
Which parameters do you monitor throughout treatment with tofacitinib?
Section III:
Best Practices and Optimization of UC Management in KSA
3.01
On a scale from 1 to 5, how does moderate-to-severe UC affect patients’ QoL?
3.02
What is the percentage of your patients who frequently skip working days, university lectures, or family events?
3.03
Improving patients’ QoL is a treatment goal. Do you incorporate Inflammatory Bowel Disease Questionnaire (IBDQ) in your daily clinical practice?
3.04
How do you manage the impact of moderate-to-severe UC on patients’ QoL?
3.05
When do you use UC scoring systems in your daily clinical practice?
KSA: Kingdom of Saudi Arabia; ACG: American College of Gastroenterology; AGA: American Gastroenterological Association; ECCO: European Crohn’s and Colitis Organization; RHI: Robarts Histopathology Index; MES: Mayo Endoscopic Subscore; UCEIS: Ulcerative Colitis Endoscopic Index of Severity; CBC: Complete Blood Count; CRP: C-Reactive Protein; UC: Ulcerative Colitis; PRO2: Patient-Reported Outcomes; TNF: Tumor Necrosis Factor; 5-ASA: 5-Aminosalicylic Acid; BMI: Body Mass Index; QoL: Quality of Life; IBDQ: Inflammatory Bowel Disease Questionnaire; IBD: Inflammatory Bowel Disease; GP: General Practitioner.
